Investments
5+ companies
Focus
Biotech, Digital Health
Samir Kaul is a Managing Partner focused on identifying and scaling transformative companies in biotech, digital health, and climate technologies. With a track record of backing category-defining ventures, Kaul has been instrumental in supporting some of the most innovative life sciences and sustainability companies to emerge in recent years. His investment portfolio includes groundbreaking organizations such as Editas Medicine, a leader in CRISPR gene editing; Ginkgo Bioworks, a pioneer in synthetic biology; 23andMe, the consumer genomics platform; Intrexon, a synthetic biology company; and LanzaTech, which commercializes carbon capture and utilization technology. Kaul's investment thesis centers on companies leveraging cutting-edge science and technology to solve critical challenges in human health and environmental sustainability. His deep sector expertise and commitment to supporting founders through scaling make him a respected voice in venture capital's most dynamic and impactful
Samir Kaul is a Managing Partner.
Samir's investment focus spans Biotech, Digital Health, Climate. This specialization allows for deep domain knowledge and strong network effects that benefit portfolio companies.
Notable investments in Samir's portfolio include 23andMe, Editas Medicine, Ginkgo Bioworks. These companies reflect a pattern of backing high-potential startups across their focus sectors.
Samir Kaul is a venture capital investor, focused on Biotech, Digital Health, Climate.
Samir Kaul focuses on investments in Biotech, Digital Health, Climate. These focus areas reflect their domain expertise and the types of startups they actively seek to back.
Samir Kaul's notable portfolio investments include Editas Medicine, Intrexon, Ginkgo Bioworks, 23andMe, LanzaTech. These companies span multiple sectors and stages, reflecting a track record of identifying high-potential startups.